FOSFOHLYV

Active material: Glycyrrhizic acid, phospholipids
When ATH: A05BA
CCF: Hepatoprotector with immunomodulatory and antiviral effect
ICD-10 codes (testimony): B15, B16, B17.1, B18.1, B18.2, K70, K71, K73, K74, L20.8, L40
When CSF: 11.16.01
Manufacturer: OAO Pharmstandard-Leksredstva (Russia)

Pharmaceutical form, composition and packaging

Capsules hard gelatin, №0, with an orange body and black cap; contents of capsules – granulated powder from white with a slightly yellowish white to light-yellow color, with low specific smell.

Excipients: microcrystalline cellulose, calcium carbonate, calcium stearate, talc, colloidal silicon dioxide (aэrosyl).

The composition of the shell capsules: Titanium dioxide (E171), iron oxide red (E172), metilparagidroksiʙenzoat (metilgidroksiʙenzoat), propilparagidroksibenzoat (propyl), acetic acid, gelatin; or titanium dioxide (E171), iron oxide red (E172), gelatin.

The composition of the capsule caps: Titanium dioxide (E171), iron oxide black (E172), metilparagidroksiʙenzoat (metilgidroksiʙenzoat), propilparagidroksibenzoat (propyl), acetic acid, gelatin; or titanium dioxide (E171), iron oxide black (E172), gelatin.

10 PC. – packings Valium planimetric (2) – packs cardboard.
10 PC. – packings Valium planimetric (3) – packs cardboard.
10 PC. – packings Valium planimetric (5) – packs cardboard.
30 PC. – Plastic containers (1) – packs cardboard.
50 PC. – Plastic containers (1) – packs cardboard.
100 PC. – Plastic containers (1) – packs cardboard.
200 PC. – Plastic containers (1) – packs cardboard.
300 PC. – Plastic containers (1) – packs cardboard.

Valium for drug of a solution for / in as masses of white to light yellow in colour.

Excipients: maltose.

2.5 g – bottles (5) – packs cardboard.
2.5 g – bottles (10) – packs cardboard.

Pharmacological action

Combined preparation. Renders the membranes, hepatoprotective and antiviral effect.

Phosphatidylcholine (the active ingredient of phospholipids) is the basic structural element of cellular and subcellular membranes, able to restore their structure and function when damaged, providing CITO-protective effect. Normalizes protein and lipid exchanges, prevents loss of gepatocitami ferments and other active substances, Restores the metabolizing liver function, inhibits the formation of connective tissue, reducing the risk of fibrosis and cirrhosis.

Glicirat (glitzirrizinova acid and salts) It has anti-inflammatory action, Suppresses reproduction viruses in the liver and other organs through stimulation of production of interferons, enhancing phagocytosis, increase the activity of natural killer cells (Natural killers). Provides gepatoprotectornoe effect thanks to the antioxidant and membranostabilizirujushhej activity. Potenziruet the endogenous gljukokortikosteroidov, providing the anti-inflammatory and anti-allergic effect when non-infectious lesions of the liver.

When skin lesions through membranostabilizirujushhego and anti-inflammatory action components limits the dissemination process and promotes regression of the disease.

Pharmacokinetics

Absorption

After intake of the drug components well absorbed from the digestive tract as a whole molecule, and in the form of bioactive products of hydrolysis (unsaturated fatty acids, mix, glicerretovaja acid).

Distribution

Bioactive products of hydrolysis is well distributed in the body, penetrate the liver, lungs, the skin and other organs.

Testimony

- Viral hepatitis (acute and chronic);

-fatty degeneration of the liver (gepatoz);

other lesions of the liver (Medicinal, Alcoholic, toxic);

- Cirrhosis of the liver;

-intoxication;

- Psoriasis;

-Atopic Dermatitis;

- Eczema.

Dosage regimen

Inside designate adult and older children 12 years by 1-2 capsules 3-4 times / day. Capsules are taken with food, drinking a small amount of liquid.

In/in slowly on drug is injected 10 ml 2 times per day, morning and evening for 10 days. Preliminary it is necessary to dissolve the contents 1 bottle in 10 ml of water for injection with subsequent transition to oral medication in the form of capsules.

Side effect

Dermatological reactions: When high sensitivity may cause skin rashes, which disappears after discontinuation of the drug.

Contraindications

- Pregnancy;

- Lactation (breast-feeding);

- Hypersensitivity to the drug.

FROM caution should be appointed patients with portal hypertension.

Pregnancy and lactation

The drug is contraindicated during pregnancy and lactation.

Cautions

Injection should not be mixed with other solutions.

Do not use for breeding lyophilisate saline or glucose solution.

Overdose

Currently, drug overdoses Phosphogliv^® not observed.

Drug Interactions

Patient interaction drug Rx hepatic protector Phosphogliv^® not disclosed.

Conditions of supply of pharmacies

The drug is released under the prescription.

Conditions and terms

List B. The drug should be kept out of the reach of children and the dark place at a temperature of no higher than 20° c. Shelf life of capsules – 3 year, shelf life of lyophilisate – 2 year.